Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Structural Basis of the Differential Binding of Engineered Knottins to Integrins αVβ3 and α5β1.

Van Agthoven JF, Shams H, Cochran FV, Alonso JL, Kintzing JR, Garakani K, Adair BD, Xiong JP, Mofrad MRK, Cochran JR, Arnaout MA.

Structure. 2019 Jul 16. pii: S0969-2126(19)30232-1. doi: 10.1016/j.str.2019.06.011. [Epub ahead of print]

PMID:
31353240
2.

Engineering a potent inhibitor of matriptase from the natural hepatocyte growth factor activator inhibitor type-1 (HAI-1) protein.

Mitchell AC, Kannan D, Hunter SA, Parra Sperberg RA, Chang CH, Cochran JR.

J Biol Chem. 2018 Apr 6;293(14):4969-4980. doi: 10.1074/jbc.M117.815142. Epub 2018 Jan 31.

3.

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.

Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, Parente-Pereira AC, Whilding LM, van der Stegen SJ, Woodman N, Sheaff M, Cochran JR, Spicer JF, Maher J.

Oncoimmunology. 2017 Aug 14;6(12):e1363137. doi: 10.1080/2162402X.2017.1363137. eCollection 2017.

4.

Development of a Protease Biosensor Based on a Dimerization-Dependent Red Fluorescent Protein.

Mitchell AC, Alford SC, Hunter SA, Kannan D, Parra Sperberg RA, Chang CH, Cochran JR.

ACS Chem Biol. 2018 Jan 19;13(1):66-72. doi: 10.1021/acschembio.7b00715. Epub 2017 Dec 12.

5.

Disgust but not Health Anxiety Graphic Warning Labels Reduce Motivated Attention in Smokers: A Study of P300 and Late Positive Potential Responses.

Cochran JR, Kydd RR, Lee JMJ, Walker N, Consedine NS.

Nicotine Tob Res. 2018 Jun 7;20(7):819-826. doi: 10.1093/ntr/ntx158.

PMID:
29065198
6.

Heterochiral Knottin Protein: Folding and Solution Structure.

Mong SK, Cochran FV, Yu H, Graziano Z, Lin YS, Cochran JR, Pentelute BL.

Biochemistry. 2017 Oct 31;56(43):5720-5725. doi: 10.1021/acs.biochem.7b00722. Epub 2017 Oct 17.

7.

High-throughput screening technologies for enzyme engineering.

Longwell CK, Labanieh L, Cochran JR.

Curr Opin Biotechnol. 2017 Dec;48:196-202. doi: 10.1016/j.copbio.2017.05.012. Epub 2017 Jun 15. Review.

PMID:
28624724
8.

A novel protein-engineered hepatocyte growth factor analog released via a shear-thinning injectable hydrogel enhances post-infarction ventricular function.

Steele AN, Cai L, Truong VN, Edwards BB, Goldstone AB, Eskandari A, Mitchell AC, Marquardt LM, Foster AA, Cochran JR, Heilshorn SC, Woo YJ.

Biotechnol Bioeng. 2017 Oct;114(10):2379-2389. doi: 10.1002/bit.26345. Epub 2017 Jun 29.

9.

Engineered ligand-based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis.

Kapur S, Silverman AP, Ye AZ, Papo N, Jindal D, Blumenkranz MS, Cochran JR.

Bioeng Transl Med. 2017 Mar;2(1):81-91. doi: 10.1002/btm2.10051. Epub 2017 Feb 17.

10.

Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses.

Kwan BH, Zhu EF, Tzeng A, Sugito HR, Eltahir AA, Ma B, Delaney MK, Murphy PA, Kauke MJ, Angelini A, Momin N, Mehta NK, Maragh AM, Hynes RO, Dranoff G, Cochran JR, Wittrup KD.

J Exp Med. 2017 Jun 5;214(6):1679-1690. doi: 10.1084/jem.20160831. Epub 2017 May 4.

11.

Targeting ligand-receptor interactions for development of cancer therapeutics.

Kim JW, Cochran JR.

Curr Opin Chem Biol. 2017 Jun;38:62-69. doi: 10.1016/j.cbpa.2017.03.010. Epub 2017 Mar 31. Review.

PMID:
28371692
12.

Measurements of translation initiation from all 64 codons in E. coli.

Hecht A, Glasgow J, Jaschke PR, Bawazer LA, Munson MS, Cochran JR, Endy D, Salit M.

Nucleic Acids Res. 2017 Apr 20;45(7):3615-3626. doi: 10.1093/nar/gkx070.

13.

Dual display of proteins on the yeast cell surface simplifies quantification of binding interactions and enzymatic bioconjugation reactions.

Lim S, Glasgow JE, Filsinger Interrante M, Storm EM, Cochran JR.

Biotechnol J. 2017 May;12(5). doi: 10.1002/biot.201600696. Epub 2017 Apr 20.

14.

Engineering High Affinity Protein-Protein Interactions Using a High-Throughput Microcapillary Array Platform.

Lim S, Chen B, Kariolis MS, Dimov IK, Baer TM, Cochran JR.

ACS Chem Biol. 2017 Feb 17;12(2):336-341. doi: 10.1021/acschembio.6b00794. Epub 2016 Dec 20.

PMID:
27997117
15.

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.

Kariolis MS, Miao YR, Diep A, Nash SE, Olcina MM, Jiang D, Jones DS 2nd, Kapur S, Mathews II, Koong AC, Rankin EB, Cochran JR, Giaccia AJ.

J Clin Invest. 2017 Jan 3;127(1):183-198. doi: 10.1172/JCI85610. Epub 2016 Nov 28.

16.

Visual cue-specific craving is diminished in stressed smokers.

Cochran JR, Consedine NS, Lee JMJ, Pandit C, Sollers JJ 3rd, Kydd RR.

Am J Drug Alcohol Abuse. 2017 Sep;43(5):525-533. doi: 10.1080/00952990.2016.1253094. Epub 2016 Nov 21.

PMID:
27870557
17.

Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.

Kintzing JR, Filsinger Interrante MV, Cochran JR.

Trends Pharmacol Sci. 2016 Dec;37(12):993-1008. doi: 10.1016/j.tips.2016.10.005. Epub 2016 Nov 9. Review.

18.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ.

Nat Med. 2016 Dec;22(12):1402-1410. doi: 10.1038/nm.4200. Epub 2016 Oct 24.

19.

Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles.

Kintzing JR, Cochran JR.

Curr Opin Chem Biol. 2016 Oct;34:143-150. doi: 10.1016/j.cbpa.2016.08.022. Epub 2016 Sep 16. Review.

PMID:
27642714
20.

Cell-Binding Assays for Determining the Affinity of Protein-Protein Interactions: Technologies and Considerations.

Hunter SA, Cochran JR.

Methods Enzymol. 2016;580:21-44. doi: 10.1016/bs.mie.2016.05.002. Epub 2016 Aug 8.

21.

Quantitative evaluation of the occupant kinematic response of the THUMS 50th-percentile male model relative to PMHS laboratory rollover tests.

Poulard D, Zhang Q, Cochran JR, Gepner B, Kerrigan J.

Traffic Inj Prev. 2016 Sep;17 Suppl 1:101-8. doi: 10.1080/15389588.2016.1192282.

PMID:
27586110
22.

Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation.

Cox N, Kintzing JR, Smith M, Grant GA, Cochran JR.

Angew Chem Int Ed Engl. 2016 Aug 16;55(34):9894-7. doi: 10.1002/anie.201603488. Epub 2016 Jun 15.

23.

In Vivo Site-Specific Protein Tagging with Diverse Amines Using an Engineered Sortase Variant.

Glasgow JE, Salit ML, Cochran JR.

J Am Chem Soc. 2016 Jun 22;138(24):7496-9. doi: 10.1021/jacs.6b03836. Epub 2016 Jun 9.

PMID:
27280683
24.

Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.

Currier NV, Ackerman SE, Kintzing JR, Chen R, Filsinger Interrante M, Steiner A, Sato AK, Cochran JR.

Mol Cancer Ther. 2016 Jun;15(6):1291-300. doi: 10.1158/1535-7163.MCT-15-0881. Epub 2016 Mar 29.

25.

Degradable acetalated dextran microparticles for tunable release of an engineered hepatocyte growth factor fragment.

Suarez SL, Muñoz A, Mitchell A, Braden RL, Luo C, Cochran JR, Almutairi A, Christman KL.

ACS Biomater Sci Eng. 2016 Feb 8;2(2):197-204. doi: 10.1021/acsbiomaterials.5b00335. Epub 2015 Dec 14.

26.

New Antarctic Gravity Anomaly Grid for Enhanced Geodetic and Geophysical Studies in Antarctica.

Scheinert M, Ferraccioli F, Schwabe J, Bell R, Studinger M, Damaske D, Jokat W, Aleshkova N, Jordan T, Leitchenkov G, Blankenship DD, Damiani TM, Young D, Cochran JR, Richter TD.

Geophys Res Lett. 2016 Jan 28;43(2):600-610. doi: 10.1002/2015GL067439. Epub 2016 Jan 21.

27.
28.

High-throughput analysis and protein engineering using microcapillary arrays.

Chen B, Lim S, Kannan A, Alford SC, Sunden F, Herschlag D, Dimov IK, Baer TM, Cochran JR.

Nat Chem Biol. 2016 Feb;12(2):76-81. doi: 10.1038/nchembio.1978. Epub 2015 Dec 7.

29.

Engineering growth factors for regenerative medicine applications.

Mitchell AC, Briquez PS, Hubbell JA, Cochran JR.

Acta Biomater. 2016 Jan;30:1-12. doi: 10.1016/j.actbio.2015.11.007. Epub 2015 Nov 7. Review.

30.

Applications of Yeast Surface Display for Protein Engineering.

Cherf GM, Cochran JR.

Methods Mol Biol. 2015;1319:155-75. doi: 10.1007/978-1-4939-2748-7_8. Review.

31.

Biocompatibility of poly(ethylene glycol) and poly(acrylic acid) interpenetrating network hydrogel by intrastromal implantation in rabbit cornea.

Zheng LL, Vanchinathan V, Dalal R, Noolandi J, Waters DJ, Hartmann L, Cochran JR, Frank CW, Yu CQ, Ta CN.

J Biomed Mater Res A. 2015 Oct;103(10):3157-65. doi: 10.1002/jbm.a.35453. Epub 2015 Mar 27.

32.

Interpenetrating polymer network hydrogel scaffolds for artificial cornea periphery.

Parke-Houben R, Fox CH, Zheng LL, Waters DJ, Cochran JR, Ta CN, Frank CW.

J Mater Sci Mater Med. 2015 Feb;26(2):107. doi: 10.1007/s10856-015-5442-2. Epub 2015 Feb 11.

PMID:
25665845
33.

Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.

Sonnenberg SB, Rane AA, Liu CJ, Rao N, Agmon G, Suarez S, Wang R, Munoz A, Bajaj V, Zhang S, Braden R, Schup-Magoffin PJ, Kwan OL, DeMaria AN, Cochran JR, Christman KL.

Biomaterials. 2015 Mar;45:56-63. doi: 10.1016/j.biomaterials.2014.12.021. Epub 2015 Jan 13.

34.

A chemically cross-linked knottin dimer binds integrins with picomolar affinity and inhibits tumor cell migration and proliferation.

Kim JW, Cochran FV, Cochran JR.

J Am Chem Soc. 2015 Jan 14;137(1):6-9. doi: 10.1021/ja508416e. Epub 2014 Dec 22.

35.

An engineered dimeric fragment of hepatocyte growth factor is a potent c-MET agonist.

Liu CJ, Jones DS 2nd, Tsai PC, Venkataramana A, Cochran JR.

FEBS Lett. 2014 Dec 20;588(24):4831-7. doi: 10.1016/j.febslet.2014.11.018. Epub 2014 Nov 21.

36.

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.

Kariolis MS, Miao YR, Jones DS 2nd, Kapur S, Mathews II, Giaccia AJ, Cochran JR.

Nat Chem Biol. 2014 Nov;10(11):977-83. doi: 10.1038/nchembio.1636. Epub 2014 Sep 21.

37.

Cystine-knot peptides: emerging tools for cancer imaging and therapy.

Ackerman SE, Currier NV, Bergen JM, Cochran JR.

Expert Rev Proteomics. 2014 Oct;11(5):561-72. doi: 10.1586/14789450.2014.932251. Epub 2014 Aug 28. Review.

PMID:
25163524
38.

A Bioengineered Peptide that Localizes to and Illuminates Medulloblastoma: A New Tool with Potential for Fluorescence-Guided Surgical Resection.

Ackerman SE, Wilson CM, Kahn SA, Kintzing JR, Jindal DA, Cheshier SH, Grant GA, Cochran JR.

Cureus. 2014;6(9). pii: e207. doi: 10.7759/cureus.207. Epub 2014 Sep 17.

39.

Engineered knottin peptide enables noninvasive optical imaging of intracranial medulloblastoma.

Moore SJ, Hayden Gephart MG, Bergen JM, Su YS, Rayburn H, Scott MP, Cochran JR.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14598-603. doi: 10.1073/pnas.1311333110. Epub 2013 Aug 15.

40.

Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics.

Kariolis MS, Kapur S, Cochran JR.

Curr Opin Biotechnol. 2013 Dec;24(6):1072-7. doi: 10.1016/j.copbio.2013.03.017. Epub 2013 Apr 12. Review.

PMID:
23587963
41.

Engineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imaging.

Moore SJ, Leung CL, Norton HK, Cochran JR.

PLoS One. 2013;8(4):e60498. doi: 10.1371/journal.pone.0060498. Epub 2013 Apr 3.

42.

A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging.

Jiang H, Moore SJ, Liu S, Liu H, Miao Z, Cochran FV, Liu Y, Tian M, Cochran JR, Zhang H, Cheng Z.

Amino Acids. 2013 Feb;44(2):673-81. doi: 10.1007/s00726-012-1391-y. Epub 2012 Sep 4.

PMID:
22945905
43.

111In-labeled cystine-knot peptides based on the Agouti-related protein for targeting tumor angiogenesis.

Jiang L, Miao Z, Kimura RH, Silverman AP, Ren G, Liu H, Lu H, Cochran JR, Cheng Z.

J Biomed Biotechnol. 2012;2012:368075. doi: 10.1155/2012/368075. Epub 2012 Apr 11.

44.

Diffusion of protein through the human cornea.

Charalel RA, Engberg K, Noolandi J, Cochran JR, Frank C, Ta CN.

Ophthalmic Res. 2012;48(1):50-5. doi: 10.1159/000329794. Epub 2012 Mar 2.

45.

Engineering knottins as novel binding agents.

Moore SJ, Cochran JR.

Methods Enzymol. 2012;503:223-51. doi: 10.1016/B978-0-12-396962-0.00009-4.

PMID:
22230571
46.

PET Imaging of Integrin Positive Tumors Using F Labeled Knottin Peptides.

Liu S, Liu H, Ren G, Kimura RH, Cochran JR, Cheng Z.

Theranostics. 2011;1:403-12. Epub 2011 Dec 21.

47.

Discovery of improved EGF agonists using a novel in vitro screening platform.

Lui BH, Cochran JR, Swartz JR.

J Mol Biol. 2011 Oct 21;413(2):406-15. doi: 10.1016/j.jmb.2011.08.028. Epub 2011 Aug 23.

PMID:
21888916
48.

Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and alphavbeta3 integrin.

Papo N, Silverman AP, Lahti JL, Cochran JR.

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14067-72. doi: 10.1073/pnas.1016635108. Epub 2011 Aug 8.

49.

Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists.

Jones DS 2nd, Tsai PC, Cochran JR.

Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13035-40. doi: 10.1073/pnas.1102561108. Epub 2011 Jul 25.

50.

Toward the development of an artificial cornea: improved stability of interpenetrating polymer networks.

Hartmann L, Watanabe K, Zheng LL, Kim CY, Beck SE, Huie P, Noolandi J, Cochran JR, Ta CN, Frank CW.

J Biomed Mater Res B Appl Biomater. 2011 Jul;98(1):8-17. doi: 10.1002/jbm.b.31806. Epub 2011 Apr 18.

PMID:
21504051

Supplemental Content

Loading ...
Support Center